Funded by the European Union (DTRIP4H, No. 101188432). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the granting authority. Neither the European Union nor the granting authority can be held responsible for them.

@DTRIP4H CONSORTIUM

DTRIP4H Meets with Its Ethical Advisory Board to Review Project Progress
DTRIP4H holds second online EAB meeting to review ethical progress and next steps.
On 23 October 2026, the DTRIP4H project held its second Ethical Advisory Board (EAB) meeting, bringing together independent ethics experts and consortium representatives to review the project's progress in addressing ethical challenges and ensuring responsible research and innovation.
The meeting was attended by all four EAB members - P. Fedele, C. Gavrilovici, A. Rostami and M. Sharp - alongside F. Carraro & M. Melli representing consortium partner Chino (IT).
ππ¦π·πͺπ¦πΈπͺπ―π¨ ππ΅π©πͺπ€π’π ππ³π°π¨π³π¦π΄π΄ π’π―π₯ ππ¦πΊ ππ©π’πππ¦π―π¨π¦π΄
Building on the first EAB meeting held in July 2025 and the Board's initial recommendations, the second meeting focused on the progress made in addressing ethical considerations across DTRIP4H's five use cases.
Discussions covered key topics including the protection of personal and sensitive health data, informed consent, the ethical use of human tissue samples, and the responsible development and application of artificial intelligence (AI).
Particular attention was given to the implementation of trustworthy AI principles, including transparency, explainability, human oversight and the prevention of algorithmic bias.
The meeting also provided an opportunity to revisit recommendations from the first EAB report, consider the consortium's responses to identified ethical issues, and discuss the findings and recommendations presented in the second Board report.
ππ΅π³π¦π―π¨π΅π©π¦π―πͺπ―π¨ ππ°π―π΅πͺπ―πΆπ°πΆπ΄ ππ΅π©πͺπ€π’π ππ·π¦π³π΄πͺπ¨π©π΅
A key focus of the meeting was ensuring that ethical considerations remain an integral part of the project's development.
The Board discussed the project's living risk register, designed to identify and monitor evolving AI-related risks, including privacy, bias, safety, governance and societal acceptance. Regular reviews of this register will help ensure that ethical safeguards continue to evolve alongside technological developments and project activities.
The meeting also highlighted the importance of assessing the practical measures adopted by the consortium to address previously identified ethical challenges and support compliance with relevant ethical and regulatory requirements.
ππ¦πΉπ΅ ππ΅π¦π±π΄ π’π―π₯ ππ°π―π΅πͺπ―πΆπ¦π₯ ππ°πππ’π£π°π³π’π΅πͺπ°π―
The meeting concluded with a clear set of follow-up actions to support ongoing ethical oversight.
The Board was invited to provide feedback on the second EAB report by 6 November 2026, with finalisation of the report planned for mid-November. Looking ahead, the consortium and EAB will continue collaborating through regular reviews, including updates to the living risk register every six months and the organisation of subsequent Board meetings.
These activities are intended to ensure that potential ethical risks are identified, assessed and addressed throughout the project's lifecycle.
Through continued engagement with its independent Board, DTRIP4H reinforces its commitment to responsible innovation, the protection of individual rights and the development of trustworthy digital health technologies.
We sincerely thank all Board members for generously volunteering their time and expertise to support the DTRIP4H project!
Learn more about the Board and its members here: https://www.dtrip4h.eu/ethical-advisory-board
.jpg)






